NAD+

Also known as: Nicotinamide adenine dinucleotide

**Mechanism of Action** NAD⁺ (nicotinamide adenine dinucleotide) functions as a central redox cofactor in cellular metabolism, shuttling electrons in oxidation-reduction reactions critical for glycolysis, the tricarboxylic acid cycle, and oxidative phosphorylation. Beyond its redox role, NAD⁺ serves as a substrate for enzymes including sirtuins (e.g., SIRT1–7), poly(ADP-ribose) polymerases (PARPs), and CD38/157 ectoenzymes. Sirtuin activation modulates mitochondrial biogenesis, DNA repair, and stress resistance via deacetylation of targets such as PGC-1α and p53, while PARP activity consumes NAD⁺ during DNA damage response. Age-related NAD⁺ decline is hypothesized to impair these pathways, driving interest in supplementation strategies (e.g., nicotinamide riboside, NMN) to restore cellular NAD⁺ pools. **Key Research Findings** Preclinical studies demonstrate that NAD⁺ precursors enhance mitochondrial function, improve insulin sensitivity, and extend healthspan in rodent models of aging and metabolic disease. For example, nicotinamide riboside supplementation elevates NAD⁺ levels, activates SIRT1, and ameliorates high-fat diet-induced glucose intolerance. In human trials, short-term NAD⁺ precursor administration shows favorable safety profiles and modest improvements in metabolic markers (e.g., lipid profiles, blood pressure), though robust evidence for anti-aging or disease-modifying effects remains limited. Mechanistically, NAD⁺ restoration reduces oxidative stress and inflammation via sirtuin-mediated pathways, but translation to clinical endpoints (e.g., lifespan extension) is unproven. **Clinical Relevance** NAD⁺ restoration is under investigation for age-associated conditions including metabolic syndrome, neurodegeneration, and cardiovascular disease. Current experimental interventions (e.g., oral NR, NMN) are not FDA-approved for therapeutic use, and long-term efficacy/safety data are lacking. While promising in preclinical models, clinical applications remain speculative, with ongoing trials evaluating dosing, bioavailability, and disease-specific outcomes. For research purposes only — not medical advice.

Key data

Research & studies

Frequently asked questions

Related peptides